Multiple myeloma (MM) arises from malignant immunoglobulin (Ig)-secreting plasma cells and remains an incurable, often lethal disease despite therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by deploying a kinaseendoribonuclease module to activate the transcription factor XBP1s. MM cells may co-opt the IRE1α-XBP1s pathway; however, the validity of IRE1α as a potential MM therapeutic target is controversial. Genetic disruption of IRE1α or XBP1s, or pharmacologic IRE1α kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice and augmented efficacy of two established frontline antimyeloma agents, bortezomib and lenalidomide. Mechanistically, IRE1α perturbation inhibited expression of key components of the endoplasmic reticulum-associated degradation machinery, as well as secretion of Ig light chains and of cytokines and chemokines known to promote MM growth. Selective IRE1α kinase inhibition reduced viability of CD138 + plasma cells while sparing CD138 − cells derived from bone marrows of newly diagnosed or posttreatment-relapsed MM patients, in both US-and European Union-based cohorts. Effective IRE1α inhibition preserved glucose-induced insulin secretion by pancreatic microislets and viability of primary hepatocytes in vitro, as well as normal tissue homeostasis in mice. These results establish a strong rationale for developing kinase-directed inhibitors of IRE1α for MM therapy.
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multiple myeloma | endoplasmic reticulum stress | unfolded protein response | inositol-requiring enzyme 1 | kinase inhibitors M ultiple myeloma (MM) is the second most common human hematologic cancer. It carries a lifetime risk of 0.7% and occurs mainly in older individuals. MM is caused by bone marrow infiltration by malignant, monoclonal immunoglobulin (Ig)-secreting plasma cells (1) . Despite significant therapeutic advances-including proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and anti-CD38 antibodies-MM remains mainly incurable, with acquired resistance to all available agents, and a 5-y survival rate of 49% (2) . Considering the growth of aging populations in many countries, there is an urgent unmet need for development of novel MM therapies.
The endoplasmic reticulum (ER) ensures precise folding of newly synthesized secretory proteins. Upon elevated cellular demand for protein secretion-for example, when mature B cells differentiate into Ig-secreting plasma cells-insufficient ER capacity causes accumulation of unfolded proteins (UPs) in the ER lumen. This activates a sensing-signaling network dubbed the UP response (UPR) to orchestrate ER adaptation and reestablish homeostasis (3) (4) (5) (6) . The mammalian UPR employs three pivotal ER-resident transmembrane sensors: inositol-requiring enzyme
Significance
Multiple myeloma (MM) is a lethal malignancy arising from plasma cells. MM cells experience endoplasmic reticulum (ER) stress due to immunoglobulin hyperproduction. The ER-resident sensor IRE1α mitigates ER stress by expanding protein-folding and secretion capacity, while supporting proteasomal degradation of ER misfolded proteins. IRE1α elaborates these functions by deploying a cytoplasmic kinase-RNase module to activate the transcription factor XBP1s. Although IRE1α has been implicated in MM, its validity as a potential therapeutic target-particularly as a kinase-has been unclear. Using genetic and pharmacologic disruption, we demonstrate that the IRE1α-XBP1s pathway is critical for MM tumor growth. We further show that the kinase domain of IRE1α is an effective and safe potential smallmolecule target for MM therapy.
1 α (IRE1α), protein kinase-like ER kinase (PERK), and activating transcription factor-6 (ATF6). UP detection by the ERluminal domain of each sensor engages the cytoplasmic moiety to adjust the ER's protein-folding, secretory, and degradative capacities and alleviate ER stress. If adaptation fails and stress becomes overwhelming, the UPR triggers apoptosis (7) . Conserved from yeast to primates, IRE1α harbors lumenal, transmembrane, and cytosolic regions: The cytoplasmic part contains a serine/ threonine kinase domain and a tandem endoribonuclease (RNase) module (8, 9) . IRE1α activation involves oligomerization, kinase transautophosphorylation, and RNase activation (9) (10) (11) (12) . The RNase cleaves the mRNA encoding unspliced X-box protein 1 (XBP1u), removing a 26-nucleotide intron, and triggering RtcB -mediated ligation of spliced XBP1 (XBP1s) (3) (4) (5) 13) . The XBP1s protein acts as a transcription factor that stimulates multiple genes including chaperones and disulfide isomerases that facilitate protein folding (14) (15) (16) . XBP1s also induces key components of ER-associated degradation (ERAD), which promotes retrotranslocation of UPs into the cytoplasm, followed by their ubiquitination and proteasomal disposal (14, 17) . An alternative IRE1α activity-termed regulated IRE1α-dependent decay (RIDD)-cleaves ER-associated mRNAs to abate translational load (18, 19) and suppress apoptosis (20, 21) .
Because plasma-cell differentiation requires IRE1α and XBP1s (22) (23) (24) , and because cancer cells often co-opt normal stressresponse pathways to support malignant growth in hostile microenvironments (25) , it has been proposed that the IRE1α-XBP1s pathway may represent a therapeutically useful vulnerability in MM (26) (27) (28) . Supporting this hypothesis, transgenic expression of XBP1s in B cells drove MM-like pathology in mice (29) , and high XBP1s levels correlated with worse prognosis in MM patients (30) . XBP1s depletion by short hairpin RNAs (shRNAs) attenuated growth of certain MM cell lines in vitro, and small-molecule inhibition of IRE1α's RNase with salicylaldehyde compounds modestly attenuated human MM xenograft growth in mice (31, 32) . Standard-of-care agents such as PIs are effective in MM therapy likely because their inhibition of the 26S proteasome creates a backlog of ERAD substrates that cannot be efficiently degraded, thereby exacerbating ER stress (33) . However, lower XBP1s levels in MM cells correlated with PI resistance (33, 34) . Furthermore, although IRE1α kinase inhibition blocked XBP1s production, it failed to attenuate MM cell growth under standard tissue culture conditions in vitro (35) . A significant caveat of salicylaldehyde-based IRE1α RNase inhibitors is that the selectivity of such compounds for IRE1α is difficult to ascertain; indeed, recent work reveals that one of these compounds acts as an antioxidant due to off-target activity (36) . In addition, because XBP1s depletion drives hyperphosphorylation of IRE1α (20, 37) , alternative, XBP1s-independent IRE1α functions-for example, activation of c-Jun N-terminal kinase (JNK) (38)-also may impact MM cells. Whether IRE1α can be targeted effectively and safely via its kinase domain to inhibit MM tumor growth under conditions that more faithfully represent this disease remains an open question.
Our results demonstrate that the IRE1α-XBP1s pathway plays a critical role in supporting MM cell growth in vitro in 3D culture settings, as well as in vivo in subcutaneous (s.c.) as well as orthometastatic tumor xenografts. Furthermore, selective small-molecule IRE1α kinase inhibition reduced viability of malignant MM cells in patient-derived bone marrows yet spared accompanying normal cells; it also preserved insulin secretion by pancreatic microislets and viability of primary hepatocytes in vitro and was well tolerated at therapeutically effective doses in mice. Together, these findings provide a compelling rationale for targeting IRE1α via its kinase domain in MM. of IRE1α for MM cell growth, we first used a doxycycline (Dox)-inducible shRNA-based knockdown approach. As expected, Doxdriven anti-IRE1α shRNA induction markedly decreased IRE1α and XBP1s protein levels in KMS-11, OPM-2, and RPMI-8226 MM cells (Fig. 1B) . Importantly, Dox-induced IRE1α depletion profoundly inhibited proliferation of these three cell lines upon 3D growth as single spheroids on ultralow attachment (ULA) plates, as evident by fluorescence imaging (Fig. 1 C-E) . In contrast, Dox treatment of the parental KMS-11 cells did not alter growth (SI Appendix, Fig. S1 B and C). IRE1α knockdown also inhibited 3D growth of KMS-11 cells as multiple spheroids on Matrigel, as determined via an Incucyte S3 instrument (SI Appendix, Fig. S1 D and E). While Dox treatment did not affect viability, as measured by CellTiter-Glo, of parental KMS-11 cells cultured on Matrigel, Dox-induced IRE1α depletion led to a substantial loss of viability (SI Appendix, Fig. S1 F-H) . Thus, three genetically diverse MM cell lines (39) displayed significant dependence on IRE1α for 3D growth-a modality that more faithfully reflects in vivo tumor settings than the conventional 2D culture used in earlier work (35) . To examine the relative importance of XBP1s for MM tumor growth in vivo, we disrupted the XBP1 gene by CRISPR/Cas9 in KMS-11 cells. Similar to the IRE1α KO clones, two independent XBP1 KO clones failed to grow appreciably upon s.c. injection into C.B-17 SCID mice, while parental IRE1α WT cells formed tumors as expected ( Fig. 2C and SI Appendix, Fig. S2E ). Thus, in vivo growth of KMS-11 tumor xenografts requires the IRE1α-XBP1s pathway.
To ascertain whether IRE1α depletion alone, or its combination with standard anti-MM therapies, affects growth of preestablished tumors, we allowed s.c. implanted KMS-11 or RPMI-8226 cells carrying Dox-inducible shRNAs against IRE1α or nontargeting control (NTC) to form palpable tumors of ∼200 mm 3 and then initiated treatment with Dox. While NTC shRNA induction had no impact on tumor growth, IRE1α knockdown substantially suppressed tumor progression, in conjunction with a marked decrease in XBP1s protein levels; this led to 61% tumor-growth inhibition (TGI) in KMS-11 and 70% TGI in RPMI-8226 xenografts (Fig. 2 D and E and SI Appendix, Fig.  S2 F-J) . Furthermore, treatment in the KMS-11 model with the maximum tolerated dose (MTD) of the PI bortezomib led to 54% TGI, while the combination of IRE1α knockdown and bortezomib treatment afforded 91% TGI (P < 0.05 compared with IRE1α knockdown alone) ( Fig. 2D and SI Appendix, Fig.  S2G ), indicating strong tumor attenuation. Similarly, treatment in the RPMI-8226 model with the MTD of the IMiD lenalidomide led to 61% TGI, while combination of IRE1α knockdown and lenalidomide administration achieved 110% TGI (P < 0.01 compared with IRE1α knockdown alone) ( Fig. 2E and SI Appendix, Fig. S2H ), indicating tumor regression. Together, these results show that genetic disruption of IRE1α markedly inhibits initiation and progression of MM tumor xenografts and increases sensitivity to established anti-MM agents. Thus, perturbation of IRE1α has significant potential to enhance the efficacy of MM therapy.
To explore mechanistically how disruption of IRE1α inhibits tumor growth, we examined the regulation of genes that encode key ERAD mediators (14, 17) . IRE1α or XBP1 KO in KMS-11 cells attenuated in vitro Tg-induced mRNA expression of the E3 ubiquitin ligase SYVN1, the E2 ubiquitin-conjugating enzyme UBE2J1, and factors required for the recognition and extraction of terminally misfolded proteins from the ER, namely EDEM1, DERL2, VIMP, DNAJC10, and ERLEC1 (Fig. 2F) . Similarly, IRE1α knockdown in RPMI-8226 cells reduced the constitutive mRNA levels of these ERAD machinery genes (Fig. 2G) . We next examined the secretion of Ig light chains. IRE1α KO via CRISPR/ Cas9 or knockdown via anti-IRE1α shRNA, but not anti-NTC shRNA, significantly attenuated secretion of Ig light chains by KMS-11 and RPMI-8226 cells and increased intracellular retention of light chain in the latter cells ( Upon ER stress, cells expressing WT IRE1α, but not the KD or PD mutants, displayed increased production of XBP1s at the protein and mRNA levels (Fig. 3A) . Thus, disruption of either the kinase function or the autophosphorylation sites of IRE1α in MM cells blocks RNase activation and XBP1s production. This finding is consistent with the failure of KD R IRE1α to rescue in vivo growth of KMS-11 tumor xenografts (Fig. 2B) .
Harrington et al. (35) identified kinome-selective inhibitors of IRE1α kinase, including compounds 16 and 18 (Fig. 3B ). We synthesized both molecules and confirmed their binding to a recombinant IRE1α protein comprising the kinase and RNase domains, and their ability to inhibit its RNase activity toward a synthetic XBP1-based RNA substrate, as well as cellular IRE1α activity measured by an XBP1s-luciferase reporter assay (SI Appendix, Fig. S3A ) (11, 24) . We compared the kinase selectivity of these compounds by testing 220 kinases via KinomeScan. Compound 18 displayed significantly better selectivity than 16, with >70% inhibition of only 1 off-target kinase (JNK2), compared with 7 for 16; another published IRE1α kinase inhibitor called KIRA6 (42) was poorly selective, with >70% attenuation of 64/220 kinases ( To gain structural insight into the interaction of compound 18 with its target, we cocrystallized it with purified recombinant IRE1α kinase-RNase protein and determined an X-ray structure , colored cyan and blue) bound to IRE1α. The C-terminal end of the αC-helix displays significant conformational changes between the two structures. (E) KMS-11, OPM-2, and RPMI-8226 cells were seeded on standard tissue culture plates (2D) or ULA plates followed by centrifugation to form single spheroids (3D). After 96 h, cells were lysed and analyzed by IB for indicated proteins. (F-H) Cells were seeded either in the 2D or 3D setting, treated for 150 h with vehicle (DMSO) or compound 18 at the indicated concentrations, and analyzed for cell growth by cell confluence using an Incucyte instrument (F) or cell viability using CellTiter-Glo 3D (G and H). **P ≤ 0.01, ***P ≤ 0.001.
, where residue Y628 shows the most difference in side-chain conformation (Fig. 3D) . Although we cannot rule out that crystal packing may influence this, structural changes in the Cα-helix may contribute to the improved selectivity of 18 against IRE1α. We therefore chose the latter molecule as a tool for further studies.
We next investigated the effect of compound 18 on MM cells growing on standard tissue culture plates (2D) compared with ULA plates (3D). As a prelude, we examined the activation state of the IRE1α pathway in cells growing in 2D or 3D. IB analysis of KMS-11, OPM-2, and RPMI-8226 cells suggested elevated activity of IRE1α in 3D versus 2D settings, evident by detectable increases in IRE1α protein and/or phosphorylation and in XBP1s levels (Fig. 3E) . Importantly, whereas both compound 18 and the previously published IRE1α RNase inhibitor 4μ8c (43) markedly inhibited 3D growth of all three cell lines, these inhibitors had much weaker impact on 2D growth (Fig. 3 F-H and SI Appendix, Fig. S3 H-N) . We obtained similar results with three additional B-derived, nonmyeloma cancer cell lines that expressed detectable baseline levels of IRE1α and XBP1s (SI Appendix, Fig. S3 O-R), supporting the importance of IRE1α for 3D growth of such cells.
Next, we turned to investigate the effect of compound 18 on growth of MM tumor xenografts in vivo. Upon intraperitoneal (IP) injection at 30 mg/kg, once (QD) or twice (BID) per day, in C.B-17 SCID mice, 18 achieved initial plasma concentrations of 4.3 μM and remained above 0.1 μM for ∼8 h (SI Appendix, Fig.  S4A ). These data suggested potentially sufficient exposure to this compound to attain significant, though perhaps incomplete, IRE1α inhibition in vivo. Comparable to the effect of IRE1α shRNA depletion, BID treatment of mice bearing preestablished KMS-11 tumor xenografts with 18 led to a substantial reduction in XBP1s protein, in conjunction with 51% TGI (Fig. 4A and SI Appendix, Fig. S4 B and C) . We next tested the effect of QD administration of the compound on growth of OPM-2 tumor xenografts; we observed 70% TGI, comparable to Dox-induced shRNA-mediated knockdown of IRE1α (Fig. 4B and SI Appendix, Fig. S4 D and E) . Thus, pharmacologic IRE1α kinase inhibition recapitulated the impact of shRNA-based IRE1α depletion on growth of MM xenografts.
We then turned to a more stringent orthometastatic model of MM, in which luciferase and mCherry double-labeled RPMI-8226 cells, injected into the tail vein of NSG mice, develop widespread malignant disease with bone marrow involvement over a period of 6 wk (SI Appendix, Fig. S4F ) (44) . Treatment of mice bearing established malignant disease with 18 over two subsequent weeks led to a marked reduction in tumor burden, evident by diminished luminescence (Fig. 4C) : Whereas 3/3 control mice displayed tumor progression over baseline, only 1/5 18-treated mice showed tumor progression, while another 1/5 exhibited tumor stasis, and 3/5 showed substantial tumor regression. Thus, pharmacologic inhibition of IRE1α kinase in vivo disrupts growth of MM xenografts not only in the s.c. setting but also in the more clinically relevant orthometastatic bone marrow microenvironment.
IRE1α Kinase Inhibition Reduces Viability of Patient-Derived MM Cells
While Sparing Normal Cells. Cancer cell lines may acquire further genetic or epigenetic alterations upon prolonged passage that could diverge them from their primary source. Therefore, to gain a more direct appraisal of the importance of IRE1α for primary MM cell survival, we tested the effect of compound 18 on viability of CD138 + plasma cells from the donated bone marrow or peripheral blood of MM patients clinically treated in the United States or the European Union (SI Appendix, Fig. S5A ). Incubation with 18 led to marked reductions in viability of the malignant CD138
+ MM cells, but not the associated nonmalignant CD138 − cells, in the majority of cases (Fig. 5 A and B) . In both MM cohorts, samples from newly diagnosed patients as well as subjects whose disease relapsed after 1 to 4 prior lines of therapy showed dose-dependent sensitivity to 18 ( Fig. 5 C and D) .
Comparison of the impact of 18 and 4μ8c on an additional MM bone marrow aspirate suggested greater loss of plasma-cell viability with the former (SI Appendix, Fig. S5 B and C) . Importantly, exposure to 18 did not reduce viability of CD138 + cells from three nonmalignant bone marrow aspirates (Fig. 5E) . Thus, IRE1α kinase inhibition can selectively disrupt survival of primary malignant MM cells while sparing nonmalignant hematopoietic cells, including plasma cells. The impact on both naïve and posttreatment-relapsed MM samples suggests that IRE1α inhibition has the potential to provide clinical benefit across several different lines of therapy.
We next turned to investigate whether pharmacologic IRE1α kinase inhibition disrupts normal function of other cell types. Inducible gene-knockout studies in mice have suggested that the IRE1α-XBP1s pathway may support insulin secretion by pancreatic cells (45, 46) and homeostasis of hepatocytes (47) . Therefore, we first verified the ability of compound 18 to inhibit XBP1s induction in human pancreatic islet 3D microtissues, which contain all of the endocrine cell types and can retain viability and function in culture for up to 4 wk (48). At 2.4 μM, 18 suppressed Tg-induced XBP1s production to baseline levels (Fig. 6A) , confirming effective IRE1α pathway inhibition. Importantly, 18 did not decrease viability, nor did it perturb glucose-stimulated insulin secretion even at higher concentrations up to 7.5 μM (Fig. 6 B and C) . We obtained similar results with rat pancreatic microislets (SI Appendix, Fig. S6 A and  B) . Furthermore, despite completely blocking tunicamycin-induced XBP1s expression by primary human hepatocytes at 3 μM, treatment with 18 did not impact hepatocyte viability at concentrations up to 6 μM ( Fig. 6 D and E) . In addition to these in vitro experiments, we performed a tolerability study of compound 18 in C.B-17 SCID mice by IP injection at 10, 30, or 100 mg/kg BID over 7 d. Whereas some mice did not tolerate the 100 mg/kg dose, animals administered up to 30 mg/kg completed the dosing period with only a minor weight loss compared with vehicle-treated controls, along with minimal changes in serum albumin and in the bone marrow myeloid compartment. Some peritoneal inflammation was seen in both vehicle-and 18-treated mice, likely due to the repeated IP injections. There were no other compound-related changes in hematology, serum chemistry, or organ weights; furthermore, there were no gross or microscopic pathology findings overall, notably including in secretory organs such as the pancreas and salivary glands (SI Appendix, Fig. S6 C and D) . In a separate study, dosing of 18 at 30 mg/kg QD for 3 wk did not cause significant alterations in hepatic, renal, and pancreatic endocrine functional markers in serum (SI Appendix, Fig. S6E ). Together, these results suggest that IRE1α kinase inhibition can achieve effective MM tumor disruption without overt negative effects on normal tissue homeostasis.
Discussion
MM cells may co-opt the IRE1α-XBP1s pathway to mitigate persistent ER stress, caused by Ig production and a nutrient/oxygen-poor bone marrow microenvironment (27) . However, recent studies have raised significant doubt concerning the validity of IRE1α as a potential MM therapeutic target: Lowered levels of XBP1s correlated with PI resistance in MM cells (49) , and IRE1α kinase inhibition blocked XBP1s yet did not affect MM cell viability in 2D culture (35, 49) . Although work based on salicylaldehyde small-molecule RNase inhibitors supported a protumorigenic role of IRE1α in MM (31, 32) , such compounds are highly proteinreactive, and their selectivity versus off targets is difficult to confirm (36) . Direct loss-of-function studies specifically addressing the importance of the kinase module of IRE1α for MM growth in vivo have been lacking. To interrogate the requirement of IRE1α for MM growth, we employed a series of strategies to disrupt it at the gene, transcript, or kinase level, in diverse model systems. Our in vitro studies showed that IRE1α depletion by shRNAs markedly attenuates growth of several MM cell lines in 3D spheroid settings-a scenario that was not previously investigated in connection with IRE1α. Consistent with this elevated dependency, MM cells growing in 3D showed increased baseline activity of the IRE1α pathway compared with 2D. In vivo, both IRE1α KO and XBP1s KO in KMS-11 MM cells profoundly disrupted their ability to form s.c. tumor xenografts in mice. Critically, reconstitution of WT but not kinase-dead IRE1α into KO cells rescued tumor growth, validating the conclusion that disrupted growth was specifically due to IRE1α kinase loss of function. These findings demonstrate a crucial requirement of the IRE1α pathway for in vivo MM growth, while other, kinase-or XBP1s-independent functions of IRE1α such as RIDD or JNK activation may be less important in the context of MM. IRE1α depletion by shRNAs clearly inhibited the growth of preformed s.c. KMS-11 and RPMI-8226 tumor xenografts, implicating IRE1α not only in promoting tumor initiation but also progression. Remarkably, the extent of TGI was directly comparable between IRE1α knockdown and the established frontline MM therapy agents bortezomib or lenalidomide. Furthermore, combination of IRE1α depletion with bortezomib or lenalidomide significantly increased the extent of TGI compared with respective monotherapies. Mechanistically, IRE1α knockdown decreased mRNA expression of multiple ERAD components known to be induced by XBP1s. Moreover, it diminished the ability of MM cells to secrete Ig light chains as well as several cytokines and chemokines, some of which have previously been shown to support malignant plasma cell growth in vitro and in vivo (1, 23, 33, 40) . In contrast, IRE1α disruption did not significantly alter ER morphology. Together, these results suggest that IRE1α inhibition has potential to provide significant clinical benefit, either alone or in combination with other MM therapies known to disrupt protein homeostasis (33, 50) . To further examine the requirement for IRE1α's kinase moiety, we first confirmed its importance for RNase activation by mutational perturbation of the kinase catalytic core or its target autophosphorylation sites. We then evaluated three compounds that bind to IRE1α's ATP docking site and exert allosteric inhibition of RNase activation (35, 42) . One of these, compound 18, displayed an improved ability to displace the Cα helix in the kinase domain and excellent selectivity toward IRE1α versus 220 other kinases. In keeping with the results of genetic IRE1α disruption, 18 inhibited growth of MM cells in 3D settings more substantially than in 2D. The IRE1α RNase inhibitor 4μ8c similarly attenuated 3D growth of MM cells, confirming the involvement of IRE1α. In mice, 18 displayed sufficient exposure upon IP administration to enable marked inhibition of XBP1s production in tumors. In concert, 18 significantly attenuated s.c. growth of KMS-11 and OPM-2 xenografts. Thus, pharmacologic inhibition of IRE1α via its kinase moiety recapitulated the impact of genetic IRE1α disruption on MM tumor growth.
To address the importance of IRE1α in a more clinically relevant MM microenvironment, we implemented an orthometastatic model, in which malignant MM cells injected intravenously (i.v.) home to the bone marrow to disseminate malignant disease. Treatment with 18 in this setting led to tumor stasis or regression in most of the animals, compared with aggressive tumor progression in the vehicle-treated controls. Thus, MM cells require IRE1α kinase function in vivo to sustain advanced malignant growth in the bone marrow.
Establishing the excellent kinase selectivity of compound 18 afforded a unique opportunity to examine more reliably the impact of specific IRE1α inhibition on patient-derived MM cells. Remarkably, the compound caused a substantial reduction in viability of malignant CD138
+ cells in the majority of MM patient samples, including newly diagnosed tumors as well as tumors that relapsed after 1 or more lines of prior therapy with clinically established agents. In contrast, to its effect on malignant plasma cells, 18 did not significantly reduce viability of accompanying nonmalignant cells in the same MM samples; it also spared both CD138
+ plasma cells and CD138 − cells in nonmalignant bone marrow aspirates. Treatment with the IRE1α RNase inhibitor 4μ8c also reduced viability of MM patient-derived CD138 + plasma cells, further confirming the reliance of these cells on IRE1α. In preclinical safety experiments, while 18 achieved complete XBP1s suppression in pancreatic microislets, it disrupted neither viability nor the capacity of these tissues to secrete insulin in response to glucose challenge. Similarly, 18 did not impact viability of primary human hepatocytes in vitro. In mice, at doses that effectively inhibited tumor growth, 18 did not significantly alter normal homeostasis of numerous tissues and organ systems examined, including secretory cells. Taken together, these results suggest that malignant MM cells harbor an enhanced dependency on the IRE1α-XBP1s pathway compared with nonmalignant cell types, highlighting this pathway as a unique vulnerability that could be clinically exploited to treat MM across multiple stages. Nevertheless, future testing of IRE1α inhibitors in human clinical trials will necessitate the development of orally available compounds and more comprehensive safety studies in suitable model organisms. In addition, it would be interesting to investigate the effect of such inhibitors on MM tumor growth in immunocompetent mice, in light of recent evidence that disruption of XBP1s augments antitumor immunity in syngeneic models of epithelial cancer (6) .
In conclusion, our work provides definitive preclinical evidence validating IRE1α as a potential therapeutic target for MM. IRE1α may play an important role in augmenting malignant growth of MM cells by enabling their adaptation to chronic ER stress through elevated ERAD capacity. IRE1α may also support the secretion of Ig light chains as well as cytokines and chemokines that enable survival and growth of malignant MM cells in their metabolically restrictive bone marrow microenvironment. Finally, while RNase inhibition of IRE1α also holds promise, our findings provide proof of concept that the kinase domain of IRE1α is likely to provide an effective and safe lever for small-molecule inhibition of this unique dual-function enzyme. This work therefore establishes a compelling rationale to develop clinical-grade kinase-based inhibitors of IRE1α for MM therapy.
Materials and Methods
Detailed methods are provided in SI Appendix.
Cell Culture and Experimental Reagents. KMS-11, RPMI-8226, OPM-2, NCI-H929, KMS-27, MOLP-8, LP-1, U266B1, UTMC-2, KMM-1, KMS28-PE, MOLP-2, NU-DUL-1, OCI-LY18, and NALM-6 cells were obtained from ATCC, JCRB, or DSMZ, authenticated by short tandem repeat profiles, and tested to ensure they were mycoplasma-free within 3 mo of use. All cell lines were cultured in RPMI1640 media supplemented with 10% (vol/vol) FBS (Sigma), 2 mM glutaMAX (Gibco), and 100 U/mL penicillin plus 100 μg/mL streptomycin (Gibco).
Thapsigargin (Sigma) was used at a concentration of 100 nM and tunicamycin (Sigma) at 5 μg/mL. Doxycycline was from Clontech. Compound 16/16, compound 18/18 (35), 4μ8c (43), JNK-IN-8, and SP600125 (Sigma) were dissolved in DMSO for cellular experiments and used at the indicated concentrations. Antibodies (Abs) for IRE1α (3294), β-actin (3700), and GAPDH (5174) were from Cell Signaling Technology. Ab for detection of human IgG light chains (709-005-149) was from Jackson ImmunoResearch. Abs for XBP1s and pIRE1 (21) were generated at Genentech. Secondary antibody (711-035-152) was from The Jackson Laboratory. 4μ8c were used at the indicated concentrations. After 150 h, cell viability of RPMI-8226 IRE1α sh7-5 and OPM-2 IRE1α sh9, NU-DUL-1, OCI-LY18, and NALM-6 cells was assessed using an ATP-consumption assay (CellTiter-Glo 3D; Promega) and measured in a luminescence reader (Envision; PerkinElmer). Cell confluency of KMS-11 IRE1α sh8-9 cells was measured using a real-time imaging system (IncuCyte; Essen Bioscience). Frames were captured at 4-h intervals using a 10× objective. Assays were run at least in triplicates.
Three-Dimensional Spheroid Proliferation Assays. For IRE1α knockdown experiments, KMS-11 IRE1α sh8-9-mCherry, RPMI-8226 IRE1α sh7-5-mCherry, and OPM-2 IRE1α sh9-mCherry cells were pretreated with 0.5 μg/mL Dox for 3 d before plating 1 × 10 3 cells per well in ULA 96-well plates (Corning).
For compound 18 and 4μ8c serial dilution studies in this setting, KMS-11α IRE1 sh8-9, RPMI-8226 IRE1α sh7-5 and OPM-2 IRE1α sh9, NU-DUL-1, OCI-LY18, and NALM-6 cells cells (2.5 × 10 3 cells per well) were plated in ULA 96-well plates. Compound 18 and 4μ8c were used at the indicated concentrations. Single spheroids were formed by centrifugation (1,000 rpm) for 10 min according to the manufacturer's protocol. Spheroids were imaged using an IncuCyte instrument. Frames were captured at 4-h intervals using a 4× objective and red fluorescence or cell confluence was detected. After 150 h, cell viability of was assessed using CellTiter-Glo 3D. For Matrigel assays, KMS-11 WT or IRE1α sh8-9 cells were pretreated with 0.5 μg/mL Dox for 3 d before plating 1 to 5 × 10 3 cells per well on 50 μL/well of Matrigel (Corning) into 96-well plates according to the manufacturer's protocol. To test the impact of JNK inhibition compared with compound 18 in this setting, cells were seeded on Matrigel as described and then treated with serial dilutions of 18, JNK-IN-8, or SP600125 as indicated. Multispheroids were imaged using an IncuCyte S3 instrument (Essen Bioscience).
Frames were captured at 4-h intervals using a 10× objective and cell confluency was detected, and then 150-h cell viability assessed using CellTiterGlo 3D. Cultures were maintained at 37°C throughout and run at least in triplicates. Values well were pooled and averaged across all replicates.
Human MM Samples. The effect of compound 18 on viability of MM or normal cells was measured after treatment in ex vivo culture of bone marrow aspirates or blood samples from MM patients or from normal bone marrow donors. All samples were deidentified before use in this study. For cell death assays, mononuclear cells obtained after separation on Ficoll density gradient were cultured in RPMI1640 media supplemented with 5% FCS and 3 ng/mL IL-6, with the indicated concentrations of compound 18 or vehicle control (DMSO) for 48 to 72 h. MM cells were then identified using CD138-PE staining and cell death was assessed by the loss of CD138 staining as previously described (51) . MM or normal plasma cells were identified as CD19 Pancreatic Islet 3D Microtissue Assays. Human and rodent 3D InSight pancreatic islet microtissues (InSphero AG) were generated from reconstituted dispersed human or rat pancreatic islet cells in a modified manner as described previously (48) retaining the composition of α, β, and δ cells representative of normal endocrine pancreatic islets. Cells were plated in microtiter wells (1,000 cells per drop) and allowed to form 3D microtissues of ∼120 μm in diameter over 7 d (n = 5 per treatment). Microtissues were incubated for 7 d with serial dilutions of compound 18 or vehicle control (DMSO) and then viability analyzed by CellTiter-Glo or insulin secretion analyzed after glucose challenge (16.7 mM) for 1 h by ELISA.
Human Hepatocyte Experiments. Normal primary human hepatocytes (Millipore Sigma) were cultured on collagen-coated 96-well plates and assays were performed in serum-free hepatocyte incubation media. Hepatocytes were treated with Tm (5 μg/mL) for 8 h in the presence of compound 18 or vehicle control (DMSO) at the indicated concentration and analyzed for XBP1s levels by RTqPCR or cultured for 48 h in the presence of vehicle (DMSO) or 18 at the indicated concentrations and analyzed for viability by CellTiter-Glo.
s.c. Xenograft Growth and Efficacy Studies. All procedures were approved by and conformed to the guidelines and principles set by the Institutional Animal Care and Use Committee of Genentech and were carried out in an Association for the Assessment and Accreditation of Laboratory Animal Careaccredited facility.
For tumor growth studies, 10 × 10 6 KMS-11 parental, IRE1α KO or XBP1 KO clones, or IRE1α KO +WT R IRE1α or +KD R IRE1α clones were suspended in HBSS, admixed with 50% Matrigel to a final volume of 100 μL, and injected s.c. in the right flank of 6-to 8-wk-old female C.B-17 SCID mice.
For efficacy studies, 10 × 10 6 KMS-11 NTC shRNA or IRE1α sh8-9, RPMI-8226 NTC shRNA or IRE1α sh5-7, or OPM-2 IRE1α sh9 cells were prepared and s.c. inoculated as outlined above. Tumors were monitored until they reached a mean tumor volume of ∼150 to 300 mm 3 . For efficacy studies of IRE1
shRNA knockdown, animals were randomized into the following treatment groups: 1) 5% sucrose water (provided in drinking water, changed weekly) or 2) Dox (0.5 mg/mL, dissolved in 5% sucrose water, changed 3 times per week). For efficacy studies of IRE1 shRNAs-mediated knockdown in combination with standard of care agents, bortezomib (Velcade; Millennium Pharmaceuticals) or lenalidomide (Revlimid; Celgene Corp.), mice were randomized into one of the following treatment groups: 1) vehicle (5% sucrose water); 2) Dox; 3) bortezomib (0.75 mg/kg, 100 μL total, i.v., twice per week) or lenalidomide (50 mg/kg, 100 μL total, IP, QD for five consecutive days), respectively; or 4) combination of Dox plus bortezomib, or doxycycline plus lenalidomide, respectively. For compound 18 efficacy studies, animals were randomized into one of the following treatment groups: 1) vehicle controls (35% PEG400 and 10% EtOH in water, 100 μL total, IP, QD) and 5% sucrose water; 2) Dox; or 3) compound 18 (30 mg/kg, 100 μL total, IP, QD or BID as indicated in figure  legends) .
